Effect of Brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women

Journal of Clinical Pharmacology

Volumn 53, Issue 12, 2013, Pages 1313-1321

  Stockis, Armel ^a   Rolan, Paul ^b,c  

^a UCB PHARMA   (Belgium)

^b Skelton House   (United Kingdom)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Bbrivaracetam; Combination oral contraceptive; Interaction; Pharmacodynamics; Pharmacokinetics

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; BRIVARACETAM; ESTRADIOL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FOLLITROPIN; HYDROCORTISONE; LEVONORGESTREL; LUTEINIZING HORMONE; PROGESTERONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; EVENING DOSAGE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL CYCLE; METRORRHAGIA; MORNING DOSAGE; NAUSEA; NIGHT SWEAT; NORMAL HUMAN; OPEN STUDY; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SPOTTING; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER ABDOMINAL PAIN; YOUNG ADULT;

ADULT; ANTICONVULSANTS; CONTRACEPTIVES, ORAL, COMBINED; CROSS-OVER STUDIES; DRUG INTERACTIONS; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LEVONORGESTREL; LUTEINIZING HORMONE; PROGESTERONE; PYRROLIDINONES; YOUNG ADULT;

EID: 84892960638     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.187     Document Type: Article

References (40)

1. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res. 2013;103:2- 30.
2. Kenda BM, Matagne AC, Talaga PE, et al. Discovery of 4 substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem. 2004;47:530-549.
3. Zona C, Pieri M, Carunchio I, Curcio L, Klitgaard H, Margineanu DG. Brivaracetam (ucb 34714) inhibits Na current in rat cortical neurons in culture. Epilepsy Res. 2010;88:46-54.
4. French JA, Costantini C, Brodsky A, von Rosenstiel P. Adjunctive brivaracetam for refractory partialonset seizures. A randomized, controlled trial. Neurology. 2010;75:519-525.
5. Werhahn KJ, Biton V, Johnson ME, Merschhemke M, Lu S, N01252 and N01253 Brivaracetam Study Group. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from two randomized, doubleblind, placebocontrolled trials. Epilepsia. 2010;51 (Suppl 4):Abstract p507.
6. van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partialonset seizures: A phase IIb, randomized, controlled trial. Epilepsia. 2013;54:89-97.
7. SargentiniMaier ML, Rolan P, Connell J, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol. 2007;63:680-688.
8. Rolan P, SargentiniMaier ML, Pigeolet E, Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy males. Br J Clin Pharmacol. 2008;66:71-75.
9. SargentiniMaier ML, Espie P, Coquette A, Stockis A. Pharmacokinetics and metabolism of 14Cbrivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008;36:36-45.
10. Nicolas JM, Chanteux H, Rosa M, Watanabe S, Stockis A. Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. Drug Metab Dispos. 2012;40:1466-1472.
11. SargentiniMaier ML, Sokalski A, Boulanger P, Jacobs T, Stockis A. Brivaracetam disposition in renal impairment. J Clin Pharmacol. 2012;52:1927-1933.
12. Stockis A, SargentiniMaier ML, Horsmans Y. Brivaracetam disposition in mild to severe hepatic impairment. J Clin Pharmacol. 2013;53:633-641.
13. Shorvon SD, Tallis RC, Wallace HK. Antiepileptic drugs: Coprescription of proconvulsant drugs and oral contraceptives: A national study of antiepileptic drug prescribing practice. J Neurol Neurosurg Psychiatry. 2002;72:114-115.
14. Guengerich FP. Oxidation of 17 alphaethynylestradiol by human liver cytochrome P450. Mol Pharmacol. 1988;33:500-508.
15. Carten ML, Kiser JJ, Kwara A, Mawhinney S, CuUvin S. Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz. Infect Dis Obstet Gynecol. 2012;2012:137192.
16. Fotherby K. Levonorgestrel clinical pharmacokinetics. Clin Pharmacokinet. 1995;28:203-215.
17. Burakgazi E, Harden C, Kelly JJ. Contraception for women with epilepsy. Rev Neurol Dis. 2009;6:E62-E67.
18. Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: Cause for concern Epilepsia. 2013;54:11-27.
19. Reddy DS. Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives. Expert Rev Clin Pharmacol. 2010;3:183-192.
20. Sabers A. Pharmacokinetic interactions between contraceptives and antiepileptic drugs. Seizure. 2008;17:141-144.
21. Herzog AG, Blum AS, Farina EL, et al. Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. Neurology. 2009;72:911-914.
22. Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res. 2001;47:151- 154.
23. Gaffield ME, Culwell KR, Lee CR. The use of hormonal contraception among women taking anticonvulsant therapy. Contraception. 2011;83:16-29.
24. Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK. Urinary excretion of 6 betahydroxycortisol as an in vivo marker for CYP3A induction: Applications and recommendations. Clin Pharmacol Ther. 1998;63:617-622.
25. Landgren BM, Balogh A, Shin MW, Lindberg M, Diczfalusy E. Hormonal effects of the 300 microgram norethisterone (NET) minipill. Daily gonadotrophin levels in 43 subjects during a pretreatment cycle and during the second month of NET administration. Contraception. 1979;20:585-605.
26. Haertzen CA, Hill HE, Belleville RE. Development of the addiction research center inventory (ARCI): Selection of items that are sensitive to the effects of various drugs. Psychopharmacologia. 1963;4:155-166.
27. Bond AJ, Lader MH. The use of analogue scales in rating subjective feelings. Br J Med Psychol. 1974;47:211-218.
28. Trouillas P, Takayanagi T, Hallett M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci. 1997;145:205-211.
29. RagueneauMajlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia. 2002;43:697-702.
30. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet. 1991;16:249-255.
31. El Desoky ES, Mohamed HO, Farghaly WM, Hamed SA, Hedaya MA, Siest JP. Study of urinary 6 betahydroxycortisol/cortisol ratio in spot urine sample as a biomarker of 3A4 enzyme activity in healthy and epileptic subjects of Egyptian population. Pharmacol Res. 2005;51:575-580.
32. Watkins PB, Turgeon DK, Saenger P, et al. Comparison of urinary 6 betacortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther. 1992;52:265-273.
33. Chen YC, Gotzkowsky SK, Nafziger AN, et al. Poor correlation between 6betahydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity. Br J Clin Pharmacol. 2006;62:187-195.
34. Crawford P, Chadwick DJ, Martin C, Tjia J, Back DJ, Orme M. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol. 1990;30:892-896.
35. Davis AR, Westhoff CL, Stanczyk FZ. Carbamazepine coadministration with an oral contraceptive: Effects on steroid pharmacokinetics, ovulation, and bleeding. Epilepsia. 2011;52:243-247.
36. Isojarvi JI, Tauboll E, Herzog AG. Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drugs. 2005;19:207-223.
37. Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17alphaethinylestradiol: A new look at an old drug. Clin Pharmacokinet. 2007;46:133-157.
38. Rosenberg M, Waugh MS. Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol. 1999;180:276- 279.
39. Betts T, Dutton N, Yarrow H. Epilepsy and the ovary (cutting out the hysteria). Seizure. 2001;10:220-228.
40. Stanczyk FZ, Hapgood JP, Winer S, Mishell DR, Jr. Progestogens used in postmenopausal hormone therapy: Differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013;34:171-208.